Live imaging of the mouse brain offers a rare view of α-synuclein dynamics at presynaptic terminals, and raises questions about which form of the protein triggers synaptic dysfunction.
A new grant opportunity will fund projects aimed at understanding the similarities and differences between biomarkers of Alzheimer’s and Parkinson’s diseases.
Aggressively treating high blood pressure and cholesterol in older adults with diabetes does not prevent cognitive decline, and results in more brain shrinkage.
Once considered a nuclear homebody, TDP-43 ventures out to accompany mRNAs down axons to nerve terminals where the transcripts can be turned into protein.
Proteins that interact with the Parkinson’s risk gene LRRK2 point to protein trafficking and degradation as causes of pathogenesis.
Combining exome sequencing with gene interaction analysis allowed researchers to identify 18 new genes for an inherited movement disorder. This method could lead to genes linked to other neurodegenerative diseases.
Researchers have sliced and digitally reassembled a famous brain in neuroscience to view its detailed three-dimensional architecture.
Scientists claim to turn differentiated mouse cells into pluripotent ones with a brief dip in an acid bath—no genetic tweaks necessary.
Using the transferrin receptor to deliver therapeutics to the brain is tricky—antibodies that bind too tightly stall in blood vessel cells and shut down transport.
A small study suggests that exposure to the pesticide DDT heightens the risk of developing Alzheimer’s disease.
Taking down a cellular henchman linked to a cell death pathway relieves symptoms of a lysosomal storage disorder in mice. Researchers hope the pathway could lead to a treatment.
The National Institutes of Health is testing pilot initiatives to address the problem of irreproducible scientific results.
Misfolded TDP-43 spreads along defined pathways in Alzheimer’s and frontotemporal dementia, tracing axonal routes between neurons.
Neuroligin, a synapse-building protein previously tied to autism, may play a part in Alzheimer’s disease through neuroinflammation and DNA transcription.
Data from Phase 3 solanezumab and bapineuzumab trials are formally published. Both missed their primary endpoints, but researchers gleaned insights about Alzheimer’s diagnosis and biomarkers, as well as how to proceed with amyloid immunotherapy therapy.